Literature DB >> 583230

Single-dose pharmacokinetics of the trypanosomicide benznidazole in man.

J Raaflaub, W H Ziegler.   

Abstract

The single-dose pharmacokinetics of N-benzyl-2-nitro-1-imidazole acetamide (benznidazole, Radanil) following administration of 1 tablet Radanil (100 mg) was investigated in six healthy volunteers. The absorption of the drug was fairly rapid. Peak plasma levels of 2.2--2.8 microgram/ml were reached after 3--4 h. The log c versus time curves showed little interindividual variation. The shape of the curves indicates that the drug follows the kinetics of a one-compartment model. The elimination half-lives ranged from 10.5 to 13.6 h, with a mean value of 12 h. The relative bioavailability of the compound (oral tablet versus oral solution) was checked in three of the subjects and found to be 91.7% on an average.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 583230

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  24 in total

1.  Benznidazole in Cerebrospinal Fluid: a Case Series of Chagas Disease Meningoencephalitis in HIV-Positive Patients.

Authors:  Marisa L Fernández; María E Marson; Guido E Mastrantonio; Marcelo A Corti; Ulises Fleitas; Susana C Lloveras; Nicolas Lista; Maria M Priarone; Cecilia Domínguez; Facundo Garcia-Bournissen
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.

Authors:  José A Pérez-Molina; Francesca Norman; Rogelio López-Vélez
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

3.  Population pharmacokinetics of benznidazole in adult patients with Chagas disease.

Authors:  D Soy; E Aldasoro; L Guerrero; E Posada; N Serret; T Mejía; J A Urbina; J Gascón
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.

Authors:  María Elena Marson; Jaime Altcheh; Guillermo Moscatelli; Samanta Moroni; Facundo García-Bournissen; Guido Enrique Mastrantonio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-08       Impact factor: 2.441

5.  Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.

Authors:  Rodrigo Moreira da Silva; Líliam Teixeira Oliveira; Neila Márcia Silva Barcellos; Jacqueline de Souza; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

6.  Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.

Authors:  Matthew O Wiens; Steve Kanters; Edward Mills; Alejandro A Peregrina Lucano; Silvia Gold; Dieter Ayers; Luis Ferrero; Alejandro Krolewiecki
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

7.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 8.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 9.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 10.  Antiparasitic drugs in children.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.